Evaluation of continuous ampicillin/sulbactam infusion in critically ill patients
Authors:
Open Access
- 10 March 2023
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 320, 121567
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- KDIGO Clinical Practice Guidelines for Acute Kidney InjuryNephron Clinical Practice, 2012
- β‐Lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured reviewClinical and Experimental Pharmacology and Physiology, 2012
- Pharmacokinetics of Ampicillin/Sulbactam in Critically Ill Patients with Acute Kidney Injury undergoing Extended DialysisClinical Journal of the American Society of Nephrology, 2012
- A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearanceCritical Care, 2011
- Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shockCritical Care, 2010
- Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infectionsInternational Journal of Antimicrobial Agents, 2008
- Antimicrobial Therapy in Critically Ill PatientsClinical Pharmacokinetics, 2005
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic modelAntimicrobial Agents and Chemotherapy, 1994
- Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysisAntimicrobial Agents and Chemotherapy, 1989